Accelerated Development of a Self-Replicating mRNA Bird Flu Vaccine by Arcturus Therapeutics, Backed by Gates Foundation, Advocated by the Kennedys within the HHS Department
The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to a novel self-amplifying mRNA vaccine developed by Arcturus Therapeutics, a company partly funded by Bill Gates, to tackle the H5N1 influenza A virus, often referred to as bird flu.
The fast track designation positions Arcturus Therapeutics' ARCT-2304 mRNA vaccine at the forefront of the race to combat the virus. Notably, the company's senior advisor, Dr. Peter A. Patriarca, who also advises the Gates Foundation, has a background in public health positions at the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA).
Arcturus Therapeutics' ARCT-2304 vaccine employs self-amplifying technology, meaning it can replicate once it enters cells, producing more mRNA over time. This unique feature has sparked global apprehension from experts and concerned citizens due to potential impacts on human biology and the continued production of mRNA within the body.
The fast-tracking of the self-amplifying ARCT-2304 vaccine development and review, amid rising concerns, has been facilitated by the Biomedical Advanced Research and Development Authority (BARDA) funding and the embracement of the Health and Human Services (HHS). This initiative, under Robert F. Kennedy Jr.'s tenure, might signal a shift from his previously cosidered restrained stance on mass vaccination.
The new technology boasts promising advantages, such as a stable, refrigerator-friendly formulation, which could streamline cold-chain logistics. Yet, the accelerated move towards these self-amplifying vaccines has raised questions about the safety of experimental gene therapy products being widely used, a subject of debate among the public and experts.
In Japan, where regulatory authorities approved the first public use of an Arcturus replicon vaccine (ARCT-154) for Covid-19, citizens have taken to the streets in protest. The inventor of mRNA technology, Dr. Robert Malone, described the new replicon vaccines as comparable to a "third atomic bomb."
The European Union (EU) followed suit, approving the new Arcturus self-amplifying Covid mRNA vaccines for those aged 18 and above, sparking concerns. Epidemiologist Nicolas Hulscher of the McCullough Foundation warned of a "grave mistake" in the EU's approval of ARCT-154, citing unspecified risks associated with the technology.
As with any medical intervention, the use of self-amplifying mRNA vaccines necessitates careful consideration and ongoing monitoring of their safety and efficacy profile.
Science and technology have played a significant role in the development of the ARCT-2304 mRNA vaccine, aimed at addressing the H5N1 influenza A virus. This vaccine, by Arcturus Therapeutics, has received Fast Track Designation from the FDA.
The medical-conditions and health-and-wellness implications of this self-amplifying technology have sparked global concerns, with experts and citizens expressing apprehension about its potential impacts on human biology.
As the vaccine moves towards widespread use, it's crucial to ensure truthful and transparent discussions about its safety, as debate continues among the public and experts.
